NEW YORK — Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced …
Business Line Research-driven: K. K. Rao, Managing Director, Transgene Biotek, addressing a press conference in Hyderabad on Tuesday. Also seen is S. S. Marthi, Company Secretary.
HORSHOLM, Denmark, Oct. 5, 2012 /PRNewswire/ — Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it has entered into an exclusive distribution agreement with Chiesi Farmaceutici S.p.A, a fully …
NEW YORK, Oct. 1, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue: Translational Regenerative Medicine: Market Prospects 2012-2022 http://www.reportlinker.com/p0595030/Translational-Regene…
XDx, Inc., a molecular diagnostics company that discovers, develops and commercializes high value, non-invasive tests to monitor immune status in transplant recipients and autoimmune diseases, announced today that Peter Maag, Ph.D., has joined XDx as P…
NORTHBROOK, Ill., Sept. 24, 2012 /PRNewswire/ — Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced it has submitted a …
Vical Incorporated ( VICL ) recently signed an agreement with Bristol-Myers Squibb Company ( BMY ) providing the latter with a global, non-exclusive license to its patented platform
Vical Inc. and Bristol-Myers Squibb signed a worldwide, non-exclusive license agreement for Vical's patented platform DNA immunization technology and Vaxfectin.
MANILA – Pharma companies will give as much as 80% discount for PhilHealth Package Type Z (catastrophic diseases)
Abbott Laboratories ( ABT ) recently announced that it is collaborating with Astellas Pharma Global Development for a phase III study being conducted with ASP0113 (TransVax). TransVax, a